

# Antimicrobial resistance: Public policy implications

---

Hellen Gelband

*March 23, 2017*

**Antimicrobial Resistance and One Health**

# Legislation

## 21st Century Cures Act (2016)

- Expedites approval and use of new antibiotics

## Generating Antibiotic Incentives Now (GAIN) Act (2012)


- Extends exclusivity for antibiotics for serious/life-threatening infections by 5 years
- fast track, priority review and expedited regulatory approval process for included drugs


# Pending AMR legislation

- Reinventing Antibiotic and Diagnostic Innovation (READI) Act (introduced 2015)
  - Tax credits for clinical testing of infectious disease products

## Legislation [2]

- Reinvigorating Antibiotic and Diagnostic Innovation (READI) Act [pending re-introduction]
  - Tax credit for new antibiotics or antifungals for serious/life-threatening infection and rapid diagnostic tests





# Animal bills

- **Preventing Antibiotic Resistance Act of 2017 (S. 629)**
  - Amend FDCA to preserve the effectiveness of medically important antimicrobials used to prevent, treat, control animal diseases
- **Delivering Antimicrobial Transparency in Animals (DATA) Act (introduced 2015)**
  - Increase reporting requirements for the use of antimicrobials in animals
- **Preservation of Antibiotics for Medical Treatment Act (PAMTA) (introduced 2009, 11, 13, 15)**
  - Require new animal drugs to demonstrate reasonable certainty of no harm to human health from AMR due to nontherapeutic use

# FDA guidance on growth promoters

## Guidance for Industry 213; Veterinary Feed Directive (Issued 2013; deadline for action, December 2016)

- Drug companies voluntarily commit to remove growth promotion on product labels
- Appropriate therapeutic use defined – for treatment, control and prevention
- Increased veterinary oversight
- Directives for medically important antibiotics in animal feeds




# FDA guidance on growth promoters

- Progress (January 2017)
  - “All affected drug applications have either aligned with the recommendations outlined in GFI #213, or their approvals have been voluntarily withdrawn”
  - 93 applications intended for use in water converted from OTC to prescription
  - 115 applications intended for use in feed converted from OTC to veterinary feed directive
  - 31 (100%) growth promotion indications removed
  - Too soon to see impact on levels of use

# Banning growth promoters: the European approach

- Sweden - first country to ban use of antibiotics as growth promoters in animal feed: 1986
- EU-wide ban: came into force in 2006 (passed in 2003)
- Results:
  - Some reductions in use (Netherlands, France, Italy)
  - Low-level use continues, masked as “prevention”/therapeutic use rather than growth promotion



**FIGURE 3-3: Sales of active ingredients of antibiotics for food animals in selected European countries, 2005–2012**

Source:  
CDDEP 2015,  
Elliot 2015

# AMR: Local and Global

## World Health Organization (2015)

- Every country to have NAP by May 2017

## United Nations (2016)

- High-level GA session affirms WHO deadline

## US Role?

For research, updates and tools on drug resistance  
and other global health topics,  
visit:

[www.cddep.org](http://www.cddep.org)



Thank you!



**CDDEP**

CENTER FOR  
Disease Dynamics,  
Economics & Policy

WASHINGTON DC • NEW DELHI